HOME >> MEDICINE >> NEWS
Expert calls for common sense, science in national response to medicinal herbs

CHAPEL HILL -- Because plants have been used to treat illness since before modern humans evolved and will remain popular into the foreseeable future, the nation needs to combine common sense with good science in its response to medicinal herbs.

That's the view of Dr. Varro E. Tyler, one of the world's leading experts on the subject.

"In my opinion, this is a scandalous situation," Tyler said. "Here we have products that are used by one-third of the adult population in the United States with a retail annual market value approximating $4 billion, and the FDA, by establishing artificially high proof-of-efficacy hurdles, refuses them drug approval. Compare this with the situation that has worked so well in Germany for many years in which 'reasonable' amounts of proof are accepted as evidence of efficacy for phytomedicines, allowing the products to become an integral part of mainstream medicine."

Author of more than 30 books, Tyler is distinguished professor emeritus of pharmacognosy at Purdue University and dean of pharmacy emeritus. He spoke Thursday (March 2) at the University of North Carolina at Chapel Hill at the first international scientific conference on medicinal herbs.

"The ancient origins of herbal medicine are indisputable," he said.

Archaeologists have found pollen and flower fragments from different medicinal plants in Neanderthal tombs in Iraq dating back some 60,000 years, the scholar said. Cannabis -- the marijuana plant -- is believed to have been used for more than 8,000 years in China, and opium, first produced in Mesopotamia, has been an important painkiller for some 5,400.

"The mummified human discovered in the Italian Alps in 1991 and now referred to as 'the iceman' possessed two pieces of birch fungus," Tyler said. "Scientists speculate that this 5,300-year-old human was using the fungus as a drug, possibly as a treatment for intestinal parasites."

The golden age of herbal medicine in the United States straddled th
'"/>

Contact: David Williamson
david_williamson@unc.edu
919-962-8596
University of North Carolina at Chapel Hill
1-Mar-2000


Page: 1 2 3 4

Related medicine news :

1. Expert panel calls for raising the bar in treating schizophrenia
2. Experts debate benefits, dangers of chlorine in C&EN point-counterpoint
3. Expert nurse paves the way with in-demand treatment option; Century-old brachytherapy rejuvenated
4. Expert calls for standard epinephrine doses when treating children in cardiac arrest
5. Experts to discuss new advances in IBS therapy and its affect on IBS sufferers
6. Experts to discuss emerging technologies in GI diagnosis and treatment
7. Experts to discuss the affects of non-steroidal anti-inflammatory drugs (NSAIDs)
8. Experts present new research on the hot topics of aging at GSAs Annual Meeting
9. Expert reviews cannot be trusted
10. Experts welcome major reforms to the coroners service
11. Experts meet to challenge approaches of testing and developing cancer treatments

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: